Court rules against experimental drugs for terminally ill

Share this article:

Terminally ill patients should not be permitted to obtain experimental drugs, a U.S. Court of Appeals for the District of Columbia Circuit has ruled, siding with the Food and Drug Administration.

In a reversal of a May 2006 ruling by a smaller panel of the court, the appeals court ruled that terminally ill patients do not have the right to gain access to unapproved prescription drugs even if they are potentially lifesaving.

The Abigail Alliance for Better Access to Developmental Drugs and the Washington Legal Foundation filed a lawsuit asking the Food and Drug Administration to approve experimental medications that appear effective and allow for their sale and distribution to terminally ill patients. The FDA, response, stated that such a waiver would lead to unacceptable risk. The current ruling came after the FDA appealed a three-judge panel's decision.

The opinion is at http://www.cadc.uscourts.gov.
Share this article:

More in News

Long-term care continues to lead in deal volume and value: PwC report

Long-term care continues to lead in deal volume ...

Long-term care bucked healthcare industry trends with strong merger and acquisition activity in the second quarter of 2014, according to newly released data from professional services firm PricewaterhouseCoopers.

Empowering nurse practitioners could reduce hospitalizations from SNFs, study finds

Granting more authority to nurse practitioners is associated with reduced hospitalization of skilled nursing facility residents, according to recently published findings.

Pioneer ACO drops out of program, despite reductions in skilled nursing utilization

A California healthcare system has become the latest dropout from the Pioneer Accountable Care Organization program, despite reducing skilled nursing facility utilization and improving its readmission rates. Sharp HealthCare announced its decision in a quarterly financial statement released Tuesday.